source
- Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment DurationNew SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.onclive · 2mo ago↗ source
- Disease Assessment and Mutational Testing in Progressive CLLExperts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.onclive · 2mo ago↗ source
- Clinical Scenario Presentation and Treatment Approach for Progressive DiseaseExperts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.onclive · 2mo ago↗ source